Physician profile
Sonya Khan
NPI 1548574999
$7,609.26
in general payments reported to CMS, 2019-2025
44 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,365 · 2020: $2,390 · 2021: $30.90 · 2022: $115 · 2023: $343 · 2024: $2,229 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,820 · Food and Beverage: $888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,820.00 |
| Food and Beverage | $888.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,095.05 | 2019-2024 | Korlym |
| Zealand Pharma US, INC. | $567.91 | 2020-2022 | |
| Ascensia Diabetes Care US INC. | $556.46 | 2023-2025 | |
| Lilly USA, LLC | $440.22 | 2019-2020 | |
| Novo Nordisk INC | $390.74 | 2019-2023 | Sogroya |
| Amarin Pharma, INC. | $379.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $323.32 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $306.47 | 2019-2020 | |
| Amgen INC. | $256.09 | 2019-2020 | |
| Companion Medical, INC. | $206.29 | 2019-2020 | |
| Dexcom, INC. | $176.20 | 2019-2020 | |
| Valeritas, INC. | $165.54 | 2019 | |
| Abbvie INC. | $164.69 | 2019-2025 | |
| Mannkind Corporation | $153.73 | 2019-2020 | |
| Abbott Laboratories | $130.78 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonya Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.